High dose therapy in localised cancer of the prostate using conformal radiotherapy techniques

Conditions

Cancer Cancer Malignant neoplasm of the prostate

Brand DH, Brüningk SC, Wilkins A, Fernandez K, Naismith O, Gao A, Syndikus I, Dearnaley DP, Tree AC, van As N, Hall E, Gulliford S, CHHiP Trial Management Group.

2021-01-0427 citations

10.1016/j.ijrobp.2020.12.041

Dose-Escalated Stereotactic Body Radiation Therapy for Prostate Cancer: Quality-of-Life Comparison of Two Prospective Trials.

Quon HC, Musunuru HB, Cheung P, Pang G, Mamedov A, D'Alimonte L, Deabreu A, Zhang L, Loblaw A.

2016-08-2917 citations

10.3389/fonc.2016.00185

Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial.

Dearnaley D, Syndikus I, Mossop H, Khoo V, Birtle A, Bloomfield D, Graham J, Kirkbride P, Logue J, Malik Z, Money-Kyrle J, O'Sullivan JM, Panades M, Parker C, Patterson H, Scrase C, Staffurth J, Stockdale A, Tremlett J, Bidmead M, Mayles H, Naismith O, South C, Gao A, Cruickshank C, Hassan S, Pugh J, Griffin C, Hall E, CHHiP Investigators.

2016-06-20916 citations

10.1016/s1470-2045(16)30102-4

Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate-risk localised prostate cancer: 2-year patient-reported outcomes of the randomised, non-inferiority, phase 3 CHHiP trial.

Wilkins A, Mossop H, Syndikus I, Khoo V, Bloomfield D, Parker C, Logue J, Scrase C, Patterson H, Birtle A, Staffurth J, Malik Z, Panades M, Eswar C, Graham J, Russell M, Kirkbride P, O'Sullivan JM, Gao A, Cruickshank C, Griffin C, Dearnaley D, Hall E.

2015-10-2896 citations

10.1016/s1470-2045(15)00280-6

Combining Dosimetry & Toxicity: Analysis of two UK Phase III Clinical trials

S. Gulliford

Journal of Physics Conference Series2014-03-24

10.1088/1742-6596/489/1/012091

Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial.

Dearnaley DP, Jovic G, Syndikus I, Khoo V, Cowan RA, Graham JD, Aird EG, Bottomley D, Huddart RA, Jose CC, Matthews JH, Millar JL, Murphy C, Russell JM, Scrase CD, Parmar MK, Sydes MR.

2014-02-26337 citations

10.1016/s1470-2045(14)70040-3

Prospective evaluation of a hydrogel spacer for rectal separation in dose-escalated intensity-modulated radiotherapy for clinically localized prostate cancer.

Eckert F, Alloussi S, Paulsen F, Bamberg M, Zips D, Spillner P, Gani C, Kramer U, Thorwarth D, Schilling D, Müller AC.

2013-01-2234 citations

10.1186/1471-2407-13-27

Independent validation of genes and polymorphisms reported to be associated with radiation toxicity: a prospective analysis study.

Barnett GC, Coles CE, Elliott RM, Baynes C, Luccarini C, Conroy D, Wilkinson JS, Tyrer J, Misra V, Platte R, Gulliford SL, Sydes MR, Hall E, Bentzen SM, Dearnaley DP, Burnet NG, Pharoah PD, Dunning AM, West CM.

2011-12-12173 citations

10.1016/s1470-2045(11)70302-3

Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial.

Dearnaley DP, Sydes MR, Graham JD, Aird EG, Bottomley D, Cowan RA, Huddart RA, Jose CC, Matthews JH, Millar J, Moore AR, Morgan RC, Russell JM, Scrase CD, Stephens RJ, Syndikus I, Parmar MK, RT01 collaborators.

2007-06-01657 citations

10.1016/s1470-2045(07)70143-2

Interventions

1. Standard 64 Gy dose of conformal radiotherapy (CRT) 2. The other group receives high dose 74 Gy CRT

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: 1. Cancer of the prostate T1b-T3a, N0, M0 2. Prostate-Specific Antigen (PSA) less than 50 ng/ml 3. World Health Organisation (WHO) 0 or 1 4. No prior radiotherapy or prostatectomy 5. No previous androgen deprivation 6. No hip prosthesis or other condition precluding radiotherapy 7. Written informed consent

Exclusion criteria

Exclusion criteria: Does not meet inclusion criteria

Design outcomes

Primary

Measure	Time frame
Local tumour control, incidence of biochemical failure, metastases, survival, side effects of radiation, quality of life and health economic resources	—

Secondary

Measure	Time frame
Not provided at time of registration	—

Countries

England, United Kingdom

Outcome results

None listed